Neuraxis, INC (NRXS) - Dilution Analysis

10-Q filing | 12.4M shares outstanding

8-K filing: From August 29, 2025 through April 20, 2026, the Company sold 1,125,281 shares of Common Stock pursuant to the At The Market Offering Agreement.

10-K filing | 11.2M shares outstanding

10-Q filing | 9.9M shares outstanding

8-K filing: Neuraxis, Inc. entered into a securities purchase agreement to sell 1,538,461 shares of common stock at $3.25 per share, with gross proceeds expected to be approximately $5.0 million. ($5.0M proceeds)

8-K filing: The company entered into a settlement agreement and issued shares through warrant exercises and preferred stock conversions. ($1.0M proceeds)

10-Q filing | 7.5M shares outstanding

10-K filing | 6.9M shares outstanding

S-3/A filing: The filing is an S-3/A registration statement for the offering of common stock and preferred stock by the company and common stock by selling stockholders, with an aggregate offering price not to exceed $25,000,000.

S-3 filing: The filing is an S-3 registration statement covering common stock and preferred stock offered by the company and selling stockholders, with an aggregate offering price not to exceed $25,000,000.

8-K filing: Neuraxis, Inc. issued 2,100,840 shares of Series B Convertible Preferred Stock to three related investors for approximately $5 million, with the transaction closing on November 13, 2024. ($5.0M proceeds)

10-Q filing | 7.2M shares outstanding

8-K filing: Neuraxis, Inc. entered into the fourth amendment to the Flagstaff SPA to change the investment amount from $5 million to $1.8 million for an additional 420,168 shares of Series B Preferred Stock, and entered into securities purchase agreements with investors for the issuance and purchase of 60,924 shares of Series B Preferred Stock for $145,000. ($0.15M proceeds)

8-K filing: On September 9, 2024, $4,935,001.90 of principal owed pursuant to the Preferred Stock Notes was automatically converted into a total of 2,073,524 shares of Preferred Stock.

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.6M shares outstanding

10-K filing | 6.6M shares outstanding

10-Q filing | 5.3M shares outstanding

10-Q filing | 5.0M shares outstanding

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock with an estimated public offering price of $6.00 per share, along with shares offered by selling stockholders, and details the company's business, risks, and financial condition.

S-1/A filing: This S-1/A filing outlines a proposed offering of 1,166,667 shares of common stock at an estimated price of $6.00 per share, along with an overview of Neuraxis, Inc.'s business, financial condition, and risk factors.

S-1/A filing: This S-1/A filing relates to a company offering shares of common stock to the public.

S-1/A filing: This S-1/A filing describes an offering of common stock, potential over-allotment, underwriter warrants, and the potential for selling stockholders to offer shares.

S-1/A filing: This S-1/A filing describes an offering of 1,875,000 Units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at an estimated public offering price of $8.00 per Unit, as well as Underwriter's Warrants to purchase a number of shares of common stock equal in the aggregate to six percent (6%) of the total number of Units issued in this offering.

S-1/A filing: This S-1/A filing outlines a proposed offering of units consisting of common stock and warrants, as well as common stock offered by selling stockholders, with the proceeds intended for sales and marketing, research and development, and debt repayment.

S-1/A filing: This S-1/A filing relates to a proposed offering of 1,875,000 shares of common stock, with an over-allotment option for the underwriter to purchase an additional 281,250 shares. The company intends to use the net proceeds for sales and marketing, research and development, repayment of convertible notes, payments to executive officers, and general corporate purposes.

S-1/A filing: The company is filing an S-1/A to offer 1,875,000 shares of common stock to the public at an estimated price between $7.00 and $9.00 and is offering the underwriter warrants to purchase common stock.

S-1 filing: This S-1 filing outlines a proposed offering of common stock and Underwriter's Warrants, with the intention to list on the Nasdaq Capital Market under the symbol "NRXS," with proceeds intended for sales and marketing, research and development, repayment of convertible notes, and general corporate purposes.